Cargando…

Estimated dose to site of loco-regional recurrence after radiotherapy in anal cancer using point of origin methods

BACKGROUND AND PURPOSE: Loco-regional recurrence (LRR) dominates the failure pattern after curative radiotherapy in anal cancer. The aim of this study was to estimate dose of LRRs in anal cancer using a point of origin-based method. METHOD AND MATERIALS: Of 321 patients with squamous cell carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Lycke Wind, Karen, Garm Spindler, Karen-Lise, Maria Lutz, Christina, Nyvang, Lars, Kronborg, Camilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929855/
https://www.ncbi.nlm.nih.gov/pubmed/36817982
http://dx.doi.org/10.1016/j.phro.2023.100424
_version_ 1784888950135980032
author Lycke Wind, Karen
Garm Spindler, Karen-Lise
Maria Lutz, Christina
Nyvang, Lars
Kronborg, Camilla
author_facet Lycke Wind, Karen
Garm Spindler, Karen-Lise
Maria Lutz, Christina
Nyvang, Lars
Kronborg, Camilla
author_sort Lycke Wind, Karen
collection PubMed
description BACKGROUND AND PURPOSE: Loco-regional recurrence (LRR) dominates the failure pattern after curative radiotherapy in anal cancer. The aim of this study was to estimate dose of LRRs in anal cancer using a point of origin-based method. METHOD AND MATERIALS: Of 321 patients with squamous cell carcinoma of the anus, 31 patients with LRR (29 local recurrences and 5 regional lymph node recurrences) were available for analysis. The recurrence volumes were delineated on recurrence magnetic resonance imaging (rMRI). Rigid and subsequent deformable co-registration of planning computerised tomography scans and rMRI were performed. Point of origin was estimated as the centre of mass (COM) and an observer-based point of origin (obs-PO). Doses to COM and obs-PO, as well as the full recurrence volume, were estimated and the relation to target volumes was extracted. RESULTS: The median minimum dose to COM was 63.8 Gy (range 32.5–65.1 Gy) and 63.7 Gy (range 35.5–65.2 Gy) to obs-PO of local recurrences. COM was included in the high dose volume (64 Gy) in 86 % of cases, and obs-PO was included in 75 % of cases. There was no difference in minimum dose to COM and obs-PO, and the median distance between the two points was 3.3 mm (range 0.6–19.8 mm). No recurrences occurred in primarily boosted lymph nodes. CONCLUSION: The majority of LLRs were located within the high dose volume indicating radioresistance as the primary cause of recurrence in anal cancer. No difference between the use of COM and obs-PO was evident.
format Online
Article
Text
id pubmed-9929855
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99298552023-02-16 Estimated dose to site of loco-regional recurrence after radiotherapy in anal cancer using point of origin methods Lycke Wind, Karen Garm Spindler, Karen-Lise Maria Lutz, Christina Nyvang, Lars Kronborg, Camilla Phys Imaging Radiat Oncol Original Research Article BACKGROUND AND PURPOSE: Loco-regional recurrence (LRR) dominates the failure pattern after curative radiotherapy in anal cancer. The aim of this study was to estimate dose of LRRs in anal cancer using a point of origin-based method. METHOD AND MATERIALS: Of 321 patients with squamous cell carcinoma of the anus, 31 patients with LRR (29 local recurrences and 5 regional lymph node recurrences) were available for analysis. The recurrence volumes were delineated on recurrence magnetic resonance imaging (rMRI). Rigid and subsequent deformable co-registration of planning computerised tomography scans and rMRI were performed. Point of origin was estimated as the centre of mass (COM) and an observer-based point of origin (obs-PO). Doses to COM and obs-PO, as well as the full recurrence volume, were estimated and the relation to target volumes was extracted. RESULTS: The median minimum dose to COM was 63.8 Gy (range 32.5–65.1 Gy) and 63.7 Gy (range 35.5–65.2 Gy) to obs-PO of local recurrences. COM was included in the high dose volume (64 Gy) in 86 % of cases, and obs-PO was included in 75 % of cases. There was no difference in minimum dose to COM and obs-PO, and the median distance between the two points was 3.3 mm (range 0.6–19.8 mm). No recurrences occurred in primarily boosted lymph nodes. CONCLUSION: The majority of LLRs were located within the high dose volume indicating radioresistance as the primary cause of recurrence in anal cancer. No difference between the use of COM and obs-PO was evident. Elsevier 2023-02-03 /pmc/articles/PMC9929855/ /pubmed/36817982 http://dx.doi.org/10.1016/j.phro.2023.100424 Text en © 2023 The Authors. Published by Elsevier B.V. on behalf of European Society of Radiotherapy & Oncology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article
Lycke Wind, Karen
Garm Spindler, Karen-Lise
Maria Lutz, Christina
Nyvang, Lars
Kronborg, Camilla
Estimated dose to site of loco-regional recurrence after radiotherapy in anal cancer using point of origin methods
title Estimated dose to site of loco-regional recurrence after radiotherapy in anal cancer using point of origin methods
title_full Estimated dose to site of loco-regional recurrence after radiotherapy in anal cancer using point of origin methods
title_fullStr Estimated dose to site of loco-regional recurrence after radiotherapy in anal cancer using point of origin methods
title_full_unstemmed Estimated dose to site of loco-regional recurrence after radiotherapy in anal cancer using point of origin methods
title_short Estimated dose to site of loco-regional recurrence after radiotherapy in anal cancer using point of origin methods
title_sort estimated dose to site of loco-regional recurrence after radiotherapy in anal cancer using point of origin methods
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929855/
https://www.ncbi.nlm.nih.gov/pubmed/36817982
http://dx.doi.org/10.1016/j.phro.2023.100424
work_keys_str_mv AT lyckewindkaren estimateddosetositeoflocoregionalrecurrenceafterradiotherapyinanalcancerusingpointoforiginmethods
AT garmspindlerkarenlise estimateddosetositeoflocoregionalrecurrenceafterradiotherapyinanalcancerusingpointoforiginmethods
AT marialutzchristina estimateddosetositeoflocoregionalrecurrenceafterradiotherapyinanalcancerusingpointoforiginmethods
AT nyvanglars estimateddosetositeoflocoregionalrecurrenceafterradiotherapyinanalcancerusingpointoforiginmethods
AT kronborgcamilla estimateddosetositeoflocoregionalrecurrenceafterradiotherapyinanalcancerusingpointoforiginmethods